Financial reports
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
22 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
Current reports
8-K
Entry into a Material Definitive Agreement
26 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5 Apr 24
8-K
Aptose Reports Results for the Fourth Quarter and Full Year 2023
26 Mar 24
8-K
Regulation FD Disclosure
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Mar 24
8-K
Regulation FD Disclosure
31 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Jan 24
8-K
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26 Jan 24
8-K
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
11 Dec 23
8-K
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
30 Nov 23
Registration and prospectus
424B4
Prospectus supplement with pricing info
26 Jan 24
S-1MEF
Registration of additional securities for an S-1
25 Jan 24
S-1/A
IPO registration (amended)
19 Jan 24
S-1/A
IPO registration (amended)
29 Dec 23
S-1/A
IPO registration (amended)
11 Dec 23
S-1
IPO registration
1 Dec 23
S-8
Registration of securities for employees
21 Sep 23
424B3
Prospectus supplement
6 Jul 23
S-1/A
IPO registration (amended)
28 Jun 23
S-1
IPO registration
16 Jun 23
Proxies
DEF 14A
Definitive proxy
18 Apr 23
PRE 14A
Preliminary proxy
7 Apr 23
DEF 14A
Definitive proxy
19 Apr 22
DEF 14A
Definitive proxy
21 Apr 21
DEF 14A
Definitive proxy
24 Apr 20
DEF 14A
Definitive proxy
8 May 19
PRE 14A
Preliminary proxy
12 Apr 19
Other
EFFECT
Notice of effectiveness
26 Jan 24
CORRESP
Correspondence with SEC
24 Jan 24
CORRESP
Correspondence with SEC
24 Jan 24
UPLOAD
Letter from SEC
5 Dec 23
EFFECT
Notice of effectiveness
3 Jul 23
CORRESP
Correspondence with SEC
28 Jun 23
UPLOAD
Letter from SEC
26 Jun 23
EFFECT
Notice of effectiveness
24 Oct 22
CORRESP
Correspondence with SEC
19 Oct 22
UPLOAD
Letter from SEC
19 Oct 22
Ownership